Villejuif, France – December 3, 2024
Orakl Oncology, a precision oncology startup spun out from the Gustave Roussy Institute, has raised €11 million in a seed funding round led by Singular, with participation from Bpifrance’s Grand Prix i-Lab and existing investors. This funding will support the launch of Orakl’s flagship AI-powered products, O-Predict and O-Validate, designed to transform the oncology drug development process.
Tackling Critical Challenges in Oncology
The drug development process for cancer treatments faces significant hurdles, with clinical trial success rates as low as 4%. Traditional models often falter due to fragmented and poorly predictive data. Orakl’s innovative techbio platform integrates real-world patient data with advanced cell biology to create individualized patient avatars, offering a unique approach to improving trial success rates and accelerating therapeutic discovery.
“Our mission is to de-risk clinical trials and bring transformative medicines to patients faster,” said Dr. Fanny Jaulin, CEO and Co-Founder of Orakl Oncology. “By addressing unmet needs in aggressive cancers like colorectal and pancreatic cancer, we aim to redefine precision oncology and improve patient outcomes.”
Key Products and Capabilities
Orakl’s platform leverages AI and machine learning to simulate drug responses using ex vivo patient avatars. The company’s flagship products include:
• O-Predict: Offers predictive insights into patient responses, progression-free survival, and drug efficacy.
• O-Validate: Focuses on biomarker validation and provides data-driven support for target identification and drug development.
These tools enable pharmaceutical and biotech companies to optimize clinical trial designs, identify effective drug combinations, and validate therapeutic targets with greater precision.
Strategic Growth and Industry Support
The funding will be used to expand Orakl’s business team and strengthen its collaborations with pharmaceutical companies. Notable recent hires include Jessica Atkinson, a former executive at Merck and Foundation Medicine, as Business Advisor to guide strategic partnerships.
Prof. Fabrice Barlesi, General Director of Gustave Roussy, emphasized Orakl’s groundbreaking role: “We are proud to innovate through our spin-off, Orakl, which develops ex vivo patient avatars to accelerate the discovery of next-generation cancer therapies.”
Singular General Partner Jeremy Uzan added: “Orakl’s combination of deep expertise in cancer research and cutting-edge AI positions it as a leader in precision oncology. We are thrilled to support their journey toward transforming the drug development landscape.”
A Bright Future for Precision Oncology
With a growing portfolio of €15 million in funding, Orakl is poised to become a pivotal player in the oncology space. By focusing on predictive and data-driven approaches, the company aims to address critical healthcare challenges and bring life-changing therapies to market faster.
For more information, visit orakloncology.com.
Media Contact:
Email: [email protected]
Phone: +33 1 42 00 00 00
Address: Villejuif, France
